ICDM 2024

Diabetes complications 1 Advancing frontiers in diabetic kidney disease therapeutics Chair(s): Seok Won Park, Eun Seok Kang
Thursday 10 October, 08:40~10:10
Room 3

This session delves into pioneering advancements in diabetic kidney disease therapeutics. Discussions will focus on the efficacy of GLP-1 receptor agonists, informed by insights from the FLOW study, the role of Nrf2 activators in the kidney, and the therapeutic potential of finerenone. Attendees will gain a comprehensive understanding of these innovative approaches, emphasizing their clinical implications and potential to improve outcomes for patients with diabetic kidney disease.

S4-1 Jin Hwa KimChosun University, Korea: Efficacy of GLP-1 receptor agonists in diabetic kidney disease: insights from the FLOW study

S4-2 In-Kyu LeeKyungpook National University, Korea: Nrf2 activator in the chronic diabetic kidney disease

S4-3 Jiten VoraUniversity of Liverpool, UK: Optimizing the management of CKD in association with type 2 diabetes: current trends and future direction

Panel discussion

S4-Panel 1
Shinae KangYonsei University, Korea
S4-Panel 2
Kyung Ae LeeJeonbuk National University, Korea

Diabetes complications 2 Unmasking diabetic cardiomyopathy: a deep dive into hidden realities Chair(s): Jihyun Lee, Jaetaek Kim
Friday 11 October, 11:10~12:40
Room 2

Heart failure (HF) is an underappreciated complication of diabetes. HF occurs in individuals with diabetes at higher rates, even in the absence of other HF risk factors such as coronary artery disease and hypertension. Patients with HF have impaired quality of life and a poor prognosis with a high risk of hospitalization. This session will explore the pathophysiology of cardiomyopathy and HF and discuss the latest evidence for the diagnosis and treatment of HF in patients with diabetes.

S14-1 Gary D LopaschukUniversity of Alberta, Canada: Decoding the pathophysiology of cardiomyopathy and heart failure in diabetes

S14-2 Eui Young ChoiYonsei University, Korea: From suspicion to diagnosis of heart failure in diabetes

S14-3 So Hun KimInha University, Korea: Evolving paradigms in heart failure therapy for diabetic patients

Diabetes complications 3 Neurodegeneration in diabetes mellitus; are we getting closer to a treatment? Chair(s): Chul-Hee Kim, Kwang Joon Kim
Friday 11 October, 14:20~15:50
Room 2

The mechanisms associated with complications of diabetes are no longer limited to peripheral organs. Diabetes-related cognitive impairment has now moved from a topic mainly addressed in research to the realm of clinical practice. Recently, a number of drugs and substances have shown promising potentials against diabetes-induced brain injury. This session will highlight the potential mechanisms underlying diabetes-related cognitive dysfunction and promising therapeutic agents including GLP-1/GIP for neurodegenerative diseases.

S16-1 Jae Hyun BaeSeoul National University, Korea: Hyperglycemia, insulin resistance, and cognitive function

S16-2 Christian HölscherHenan Academy of Innovations in Medical Science, China: Neuroprotective effects of GLP-1 and GIP in patients with Alzheimer or Parkinson’s disease

S16-3 Hojin ChoiHanyang University, Korea: Promising new drugs for Alzheimer's disease and cognitive impairment

구분		사전등록 (~2024년 9월 2일까지)		현장등록 (2024년 10월 9일 ~ 11일)
구분		KDA회원	비회원	KDA회원	비회원
9~11일 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	₩280,000	₩350,000	₩370,000	₩450,000
9~11일 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사 및 기타 (군의관 및 공중보건의 포함)	₩180,000	₩230,000	₩250,000	₩270,000
One-day 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	₩170,000	₩210,000	-
One-day 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사 및 기타 (군의관 및 공중보건의 포함)	₩110,000	₩140,000	-
저녁 식사	전체	₩55,000

Program details

평점안내 (For Korean)